baber/WOPTO huggingface dataset:
Patent DE-68915899-T2 (DE)
Inventor: BRANKOVAN VERA
IPC: A61K38/00
Filed: 1989-08-25
Granted: 1994-10-13
Abstract: The use of TGF- beta  to inhibit HIV infection and/or replication is described. Both mature and precursor forms of TGF- beta  are efficacious in inhibiting production of HIV. The TGF- beta  used to inhibit HIV may be obtained from natural sources or may be produced by recombinant DNA or chemical synthetic techniques. TGF- beta 1 and/or TGF- beta 2 may be used. Additionally, hybrid TGF- beta 1/ beta 2 molecules may also be utilized.
Patent DE-68925738-T2 (DE)
Inventor: LUNDBAECK STIG
IPC: F04B43/12
Filed: 1989-12-08
Granted: 1996-09-26
Abstract: A machine for converting pressure energy of a fluid into mechanical work comprises a working chamber (27, 28) the volume of which is cyclically variable in response to reciprocatory motion of a wall (20) which defines the working chamber; a reciprocatory power member (15, 16) which is displaceable by said wall under action of the pressure of the fluid on the wall during expansion of the working chamber; an inlet conduit (12) communicating with the working chamber; an outlet conduit (13) communicating with the working chamber (13); and outlet valve (22) which is closable to prevent fluid flow in the outlet conduit in the direction away from the working chamber; and a driven member (17) operatively connected with the power member. The outlet conduit comprises a gap-like passage (26) which substantially surrounds the working chamber (27, 28) and extends along the periphery thereof and which is open or openable to permit fluid flow therethrough from the working chamber substantially without any pressure drop.
Patent DE-68927480-T2 (DE)
Inventor: KINET JEAN-PIERRE
IPC: C12N1/21
Filed: 1989-10-18
Granted: 1997-05-28
Abstract: Disclosed herein is the isolation and sequencing of the cDNA coding for the  gamma  subunit of the high-affinity receptor for immunoglobulin E (IgE) on mast cells and basophils. Also disclosed is the expression of the receptor when the cDNA for its  alpha ,  beta and  gamma  subunits are simultaneously contransfected. This success in expression of IgE binding permits detailed analysis of the IgE-receptor interaction and thus enables the development of therapeutically effective inhibitors.
Patent DE-69017484-T2 (DE)
Inventor: FRIEDMAN MICHAEL
IPC: A61K9/00
Filed: 1990-03-16
Granted: 1995-07-27
Abstract: Biodegradable sustained-release compositions capable of achieving the sustained release of chlorhexidine, comprise chlorhexidine digluconate, a protein such as gelatin (which may be cross-linked) and optionally a plasticiser such as glycerin. The compositions can be formed into implant devices which may be used to treat a wide variety of diseases and conditions. The implants are especially useful in treating disease such as periodontal disease which require prolonged drug release.
Patent DE-69019726-T2 (DE)
Inventor: DAIKUZONO NORIO
IPC: A61B18/24
Filed: 1990-08-31
Granted: 1996-01-11
Abstract: USE : For applying laser beams to tissue of human or animal to perform incision, transpiration or thermotherapy, and for use when expanding constricted part caused by cholesterol in narrow passage in organic tissue e.g. blood vessel. @(33pp Dwg.No.1,2/13)@.
Patent DE-69021224-T2 (DE)
Inventor: WENZEL UDO PROF DR
IPC: A61K9/22
Filed: 1990-01-31
Granted: 1996-04-04
Abstract: The invention relates to a system for preferably peroral administration with erosion-controlled active agent release and a process for its preparation from which preferably low solubility active agents are released with delay, and in a possible combination of suitable, high solubility active agents the latter are released rapidly and with only slight delay. The active agent(s) is (are) fabricated in the usual manner with adjuvants capable of swelling, e.g. microcrystalline cellulose or starch, with adjuvants which have higher affinity to water and function as swelling controllers (e.g. polyethylene glycols, strongly hydrating inorganic compounds) and optionally with additional adjuvants. The pharmaceutical preparations prepared in this manner contribute significantly to improving the therapy of various illnesses, for when suitable and preferably low solubility active agents are incorporated, the adjustment and maintenance of therapeutically effective concentrations of active agent are ensured.
Patent DE-69027482-T2 (DE)
Inventor: CLARK BARRY PETER
IPC: A61K31/55
Filed: 1990-04-19
Granted: 1996-11-07
Abstract: Pharmaceutical compounds having the formula <CHEM> in which R<1> is hydrogen, hydroxy, nitro, cyano, halo, amino, acetamido, hydroxy-C1-4 alkyl, carboxaldehydo, C1-4 alkyl-carbonyl, carboxy, C1-4 alkoxy-carbonyl, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylsulphonyl or C1-4 alkoxy-C1-4 alkyl, R<2> is hydrogen or halo, R<3> is optionally substituted phenyl or optionally substituted phenyl ortho condensed with an optionally substituted ring selected from benzene, cyclohexane, cyclohexene, cyclopentane or cyclopentene, in which ring one of the carbon atoms may be replaced by oxygen, sulphur or nitrogen, and R<4> is hydrogen, C1-4 alkyl, C2-4 alkenyl or optionally substituted benzyl; and salts thereof.
Patent DE-69028136-T2 (DE)
Inventor: HAYASE YOSHIO
IPC: A01N41/10
Filed: 1990-05-16
Granted: 1997-01-23
Abstract: A process for preparing a compound of the formula: <CHEM> wherein A is a phenyl group or a heterocyclic group, said phenyl group and said heterocyclic group being optionally substituted with not more than three substituents, which comprises reacting a compound of the formula: <CHEM> with an aryl halide in the presence of a base. The resulting compound (A) is useful as a fungicide. There is also disclosed a compound of the formula: <CHEM>
Patent DE-69028534-T2 (DE)
Inventor: HESS RICHARD
IPC: C07C59/185
Filed: 1990-07-30
Granted: 1997-03-06
Abstract: A method is disclosed for preventing graft rejection of transplanted solid organs, in mammal recipients thereof, by administering an effective graft rejection preventative amount of succinylacetone to said mammals.
Patent DE-69032818-T2 (DE)
Inventor: VAN MOER ANDRE
IPC: C09K11/06
Filed: 1990-10-15
Granted: 1999-04-29
Abstract: New derivatives of anthracene for the emission of a blue chemiluminescent light are disclosed. The derivatives are of 9,10-bisphenylanthracene substituted at the 2 position of the anthracene ring and on the phenyl groups. The production of turquoise chemiluminescent light is also disclosed by mixing said derivatives with a green 9,10-bis(phenylethynyl)anthracene.
Patent DE-69108289-T2 (DE)
Inventor: FREEMAN RICHARD ROBERT
IPC: F04C15/00
Filed: 1991-05-08
Granted: 1995-08-03
Abstract: A method of setting up the required running tolerances in a gerotor pump having annulus and rotor meshed together and located in a body comprises pressing a cover plate (Fig.1) or equivalent as an interference fit into the body and then allowing it to relax and recover elastically to set up the required tolerances at axial ends of the gerotor set. <IMAGE>
Patent DE-69110623-T2 (DE)
IPC: A61M39/02
Filed: 1991-06-06
Granted: 1996-01-11
Abstract: A universal connector is described, being capable of both connection with female luer connectors and penetration of resealable-diaphragm connection sites. The connector comprises a tubular member defining a first tubular section having a distal end capable of resealably penetrating a latex resealable-diaphragm injection site. Aperture means are provided adjacent the distal end of the tubular member for communication with the lumen of the tubular member with the exterior. The tubular member also defines a frustoconical male luer section positioned proximally of the first tubular section and proportioned to be sealable with female luer connectors. The male luer section has a minimum diameter that is greater than the maximum diameter of the first tubular section. Annular step means are provided separating the first tubular section and male luer section, and means are provided, spaced proximally of the frustoconical male luer section, for providing connection with a fluid conduit.
Patent DE-69110794-T2 (DE)
Inventor: FEARNOT NEAL EDWARD
IPC: A61B17/22
Filed: 1991-08-15
Granted: 1995-12-07
Abstract: An ablation catheter is provided with an elongated member or shaft (110) and a plurality of helically-shaped cutting wires (104) atached to the shaft to form a cutting basket (150). Each of the cutting wires has a section formed as a circumferentially subscribing arc (105) and together the wires present a circumferential cutting area of an essentially cylindrical configuration. Each of the wires (104) comprises a first curved or straight section (123) extending from the distal end of shaft (110) to a discontinuity such as a corner or kink (125). Obstructing matter on the inner surface of a vessel cavity, such as a blood vessel or the like, is separated from the surface as the catheter is moved through the vessel. The catheter may be inserted in a vessel in a standard fashion using a wire guide (102) which extends through a longitudinal passageway in the shaft and a hub (103) interconnecting the basket wire. The shaft and basket together may be contained in an outer sheath to facilitate insertion. The outer sheath with the basket in a collapsed state in the outer sheath may be readily moved past an obstruction, and the sheath withdrawn to allow the basket to expand and come in contact with the interior surface of the vessel cavity. The proximal ends of the cutting wires extend from the shaft through a vibratory transducer, and the distal ends are connected together by a hub. Electrical current is applied to electrical terminals connected to the cutting wires at the proximal end of the shaft to heat the wires to facilitate separating obstructing matter from a vessel surface. Futhermore, the vibration transducer vibrates the cutting wires to further aid in separating plaque and obstructions from soft tissue such as the intima layer of the wall of a blood vessel.
Patent DE-69116832-T2 (DE)
Inventor: FALVARD RENE
IPC: B29D30/26
Filed: 1991-11-07
Granted: 1996-07-04
Abstract: The device comprises a turn-over bladder 1 capable of moving axially towards the centre of the drum 3 in the manner of a caterpillar track. Its movement is controlled by the inflation of a thrust bladder 2. <IMAGE>
Patent DE-69126083-T2 (DE)
Inventor: STUEBER RICHARD J
IPC: B23K31/00
Filed: 1991-09-27
Granted: 1997-11-20
Abstract: A process is provided for welding a gamma-prime precipitation-strengthened nickel base superalloy by heating the weld area and adjacent region to a ductile temperature, welding while maintaining the entire weld area and adjacent region at the ductile temperature and holding the weldment, weld area and adjacent region at the ductile temperature until the entire weld has solidified. The ductile temperature is above the aging temperature but below the incipient melting temperature of the superalloy. <IMAGE>
Patent DE-69127583-T2 (DE)
Inventor: YAMASHITA MASATAKA
IPC: C07D239/34
Filed: 1991-06-05
Granted: 1998-02-19
Abstract: A liquid crystal composition comprising at least one mesomorphic compound represented by the following formula (I): <CHEM> wherein R1 and R2 respectively denote a linear or branched alkyl group having 1 - 16 carbon atoms optionally substituted; Z1 denotes a single bond, -O-, -COO- or -OCO-, X1 denotes halogen; and A1 denotes a single bond or <CHEM> and at least one mesomorphic compound represented by the following formula (II): <CHEM> wherein R3 and R4 respectively denote an alkyl group having 2 - 16 carbon atoms optionally substituted; Y1 denotes a single bond, <CHEM>  Z2 and Z3 respectively denote a single bond, -O-, <CHEM>   <CHEM>  A2 and A3 respectively denote a single bond, <CHEM>   <CHEM> X2 and X3 respectively denote hydrogen, F, Cl, Br, -CH3, -CN or -CF3; and k is 0 or 1 with the proviso that Z2 is a single bond when A2 is a single bond, and Z3 is a single bond when A3 is a single bond and k is 0. The liquid crystal composition is easily aligned by a simple rubbing method to provide a uniform monodomain and further provides wider driving voltage and temperature margins effective for providing a practical ferroelectric liquid crystal device. <IMAGE>
Patent DE-69208885-T2 (DE)
Inventor: SMEDAL ARNE
IPC: B63B5/24
Filed: 1992-09-02
Granted: 1996-09-05
Abstract: PCT No. PCT/NO92/00139 Sec. 371 Date Jun. 28, 1994 Sec. 102(e) Date Jun. 28, 1994 PCT Filed Sep. 2, 1992 PCT Pub. No. WO93/04911 PCT Pub. Date Mar. 18, 1993.In a hull the skin plate is built up as a composite member with an outer skin, a core and an inner skin. The skin plate is placed on the framework which includes longitudinal stiffeners. The inner skin is constructed as a diaphragm element relative to the external water pressure, while the core is made as a pressure-absorbing element and the outer skin is constructed primarily as a bending stressed element. The inner skin as a diaphragm will take tensile stress and be protected against outer local stresses. The material in the core can be chosen without major requirements to be able to tolerate shearing stress. The outer skin can be dimensioned and made primarily to take local shock loads.
Patent DE-69214294-T2 (DE)
Inventor: OZIN GEOFFREY
IPC: C01B39/04
Filed: 1992-11-13
Granted: 1997-02-27
Abstract: Crystalline microporous solids, such as aluminosilicate zeolites or silica molecular sieves, are grown in a fluoride-containing, substantially non-aqueous medium to form crystals on the order 0.3-3 mm in size. This growth process involves preparing a mixture containing one or more nutrients capable of forming the crystalline microporous solid, such as a source of silica and a source of alumina; water in a controlled amount; a growth medium comprising hydrogen fluoride and a nitrogen-containing organic base, such as pyridine; and optionally an organic solvent and/or a structure-directing agent; and thereafter heating the resulting mixture for a time sufficient to produce the crystalline microporous solid.
Patent DE-69216482-T2 (DE)
Inventor: KATAKURA KAZUNORI
IPC: G02F1/133
Filed: 1992-06-17
Granted: 1997-05-15
Abstract: A display apparatus includes a matrix of electrodes formed of scanning electrodes and information electrodes. A scanning device uses a plurality of scanning methods for selecting scanning electrodes and performs the scanning methods according to respective priorities, and a driving device changes driving conditions according to the scanning methods or the priorities thereof. <IMAGE>
Patent DE-69217392-T2 (DE)
Inventor: MONNIER JOHN
IPC: C07D303/04
Filed: 1992-07-23
Granted: 1997-05-22
Abstract: Disclosed is a process for the selective epoxidation of olefins, including diolefins, having more than 2 carbon atoms by the catalytic oxidation of such an olefin in the presence of a supported, thallium-promoted, silver catalyst.
Patent DE-69219225-T2 (DE)
Inventor: NIEZINK HERMAN
IPC: A61D7/00
Filed: 1992-07-03
Granted: 1997-10-30
Abstract: Injector (1), comprising a housing to which is fixed a hollow needle (17) provided with conveyance means (3,4) for moving an object such as a transponder (22) through said needle (17). Such transponders (22) are inserted in living beings for identification purposes. Metering means (11,12) are provided in the injector (1) in order to permit the introduction of a fluid such as a disinfectant during the insertion of such objects (22). Such means comprise a storage place for fluid (11) which is connected to channel means (8) which open into the movement path of the object (22). In this way fluid is added during the positioning of the object (22). <IMAGE>
Patent DE-69221169-T2 (DE)
Inventor: REX JORN
IPC: A61M5/19
Filed: 1992-04-14
Granted: 1998-03-05
Abstract: The invention relates to an apparatus for simultaneous injection of two different kinds of preparations in a preset proportion.
Patent DE-69229993-T2 (DE)
Inventor: PARTRIDGE PETER
IPC: C22C1/00
Filed: 1992-02-24
Granted: 2000-01-13
Abstract: PCT No. PCT/GB92/00326 Sec. 371 Date Oct. 12, 1993 Sec. 102(e) Date Oct. 12, 1993 PCT Filed Feb. 24, 1992 PCT Pub. No. WO92/14852 PCT Pub. Date Sep. 3, 1992.An alloy based on titanium and containing 0.5 to 30% by weight of magnesium, calcium or lithium is produced by vapor quenching to yield a metastable solid solution of solute in titanium. Exemplified alloys containing magnesium have age hardening or solution strengthening characteristics. Vapor quenching enables these alloys to be produced despite the differences in melting temperature between solute and solvent by separate vaporization of each of the species and mixing in the vapor phase. This method provides a route to achieving rapid solidification microstructures unobtainable by other rapid solidification methods. Preferred alloys comprise Ti with 1-15% or 3-7% by weight of magnesium. The alloys may contain other strengthening ingredients currently used in titanium alloys.
Patent DE-69312307-T2 (DE)
Inventor: KEATING KENNETH
IPC: C23C14/08
Filed: 1993-10-13
Granted: 1997-12-11
Abstract: A process for producing thin films of superconducting material by bombarding a heated target with radiation from pulsed high energy UV laser to form a plume of target material, and depositing the plume on a substrate is disclosed.
Patent DE-69322271-T2 (DE)
Inventor: KIKINIS DAN
IPC: H04M1/725
Filed: 1993-06-29
Granted: 1999-04-22
Abstract: A modular notebook computer has a framework with module bays for receiving CPU modules, power modules, and peripheral function modules such as floppy and hard disk drives. The framework has a built-in compressed bus and a variety of function modules which can be plugged into any one of the module bays. Function modules include, but are not limited to, CPU, power, floppy disk, hard disk, RAM memory, LAN communication, modem, FAX communication, and data acquisition.
Patent DE-69329855-T2 (DE)
Inventor: HUNT K
IPC: H04M3/38
Filed: 1993-06-22
Granted: 2001-11-22
Abstract: The present invention describes a method for recognizing alphanumeric strings spoken over a telephone network wherein individual character recognition need not be uniformly high in order to achieve high string recognition accuracy. Preferably, the method uses a processing system having a digital processor, an interface to the telephone network, and a database for storing a predetermined set of reference alphanumeric strings. In operation, the system prompts the caller to speak the characters of a string, and characters are recognized using a speaker-independent voice recognition algorithm. The method calculates recognition distances between each spoken input character and the corresponding letter or digit in the same position within each reference alphanumeric string. After each character is spoken, captured and analyzed, each reference string distance is incremented and the process is continued, accumulating distances for each reference string, until the last character is spoken. The reference string with the lowest cumulative distance is then declared to be the recognized string.
Patent DE-69403573-T2 (DE)
Inventor: LE LANNOU MICHEL
IPC: B29C45/16
Filed: 1994-07-25
Granted: 1998-10-08
Abstract: Method of manufacturing a component by moulding, this component including an internal cavity (5), being in the form of an insert (3) produced in a first thermoplastic (2) covered, at least partially, by a layer of a second, covering thermoplastic (6). According to the invention, a backpressure is provided in the internal cavity (5) when the insert is still malleable during the step of putting the covering material (6) in place. The subject of the invention is also an application of this method to the manufacture of components, such as, in particular, vehicle door handles. <IMAGE>
Patent DE-69403854-T2 (DE)
Inventor: BURGER ARTUR
IPC: A61K31/19
Filed: 1994-03-22
Granted: 1997-11-27
Abstract: A new modification of Lifibrol is described with a melting point of 132 DEG C - 138 DEG C, particularly from 134 DEG C - 136 DEG C and a primary peak in an IR spectrum at a wave number of 3,200 - 3,400, preferably 3,250 - 3,350. The new modification of Lifibrol (modification II) is distinguished in that it allows for good crystallization and, therefore, can be formulated without problems on a large industrial scale for tablets of acceptable size and high stability.
Patent DE-69409763-T2 (DE)
Inventor: SCARLETT JOHN
IPC: C07C27/02
Filed: 1994-01-06
Granted: 1998-09-24
Abstract: Prepn. of alcohols and diols by hydrogenation of a corresponding unsatd. cpd. selected from (di)esters and lactones comprises: (a) having an hydrogenation zone contg. a granular Cu-contg. ester hydrogenation catalyst; (b) supplying to the zone a vaporous feed stream (A); (c) maintaining a temp. of 150-350 [deg]C and a pressure of 150-2000 psia in the zone; (d) recovering a reaction prod. stream of alcohol or diol; (e) supplying to the zone a stream of H2-contg. gas, which is free from the unsatd. cpd., at a reactivation temp. and for sufficient time to reactivate the catalyst. (A) contains a H2-contg. gas and 1-4C alkyl esters of 9-22C alkylcarboxylic acids, di(1-4C) diesters of 4-16C dicarboxylic acids, gamma-butyrolactone or epsilon-caprolactone. Also claimed are the following: (1) a process for reactivating a partially deactivated Cu-contg. ester hydrogenation catalyst; and (2) a further process for reactivating a partially deactivated Cu-contg. ester hydrogenation catalyst.
Patent DE-69411154-T2 (DE)
Inventor: AMKRAUT ALFRED A
IPC: A61K47/48
Filed: 1994-02-22
Granted: 1998-10-22
Abstract: Compositions and methods for the oral administration of drugs and other active agents are provided. The compositions comprise an active agent carrier particle attached to a binding moiety which binds specifically to a target molecule present on the surface of a mammalian enterocyte. The binding moiety binds to the target molecule with a binding affinity or avidity sufficient to initiate endocytosis or phagocytosis of the particulate active agent carrier so that the carrier will be absorbed by the enterocyte. The active agent will then be released from the carrier to the host's systemic circulation. In this way, degradation of degradation-sensitive drugs, such as polypeptides, in the intestines can be avoided while absorption of proteins and polypeptides from the intestinal tract is increased.
Patent DE-69413238-T2 (DE)
Inventor: CROSS PETER EDWARD
IPC: A61P13/02
Filed: 1994-08-09
Granted: 1999-01-28
Abstract: PCT No. PCT/EP94/02660 Sec. 371 Date Feb. 23, 1996 Sec. 102(e) Date Feb. 23, 1996 PCT Filed Aug. 9, 1994 PCT Pub. No. WO95/06046 PCT Pub. Date Mar. 2, 1995Compounds of formula (I):    <IMAGE>  (I)  and pharmaceutically acceptable salt and biolabile esters thereof, wherein R1 is H, C1-C4 alkyl, phenyl optionally substituted by up to three substituents independently selected from C1-C4 alkyl, C1-C4 alkoxy, halogen and CF3, or is 1-imidazolyl, 3-pyridyl or 4-pyridyl; R2 is H or C1-C4 alkyl, R3 is SO2R4 or COR4where R4 is C1-C6 alkyl, C1-C3 perfluoroalkyl(CH2)p, C3-C6 cycloalkyl(CH2)p, aryl(CH2)p, or heteroaryl(CH2)p, p being 0, 1 or 2, or R4 may be NR5R6 where R5 is H or C1-C4 alkyl and R6 is C1-C6, alkyl, C3-C6 cycloalkyl or aryl, or R5 and R6 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may optionally incorporate a carbon-carbon double bond or a further heteroatom linkage selected from O, S, NH, N(C1-C4 alkyl) and N(C1-C5 alkanoyl); X is CH2 or a direct link, with the proviso that when R1 is 1-imidazolyl then X is CH2; m is 2, or 3; n is 0, 1 or 2, and wherein the group (CH2)nNHR3 is attached at the 5-position when n is 0 or 1, or at the 5- or 4-position when n is 2. These compounds are selective TXA2 and PGH2 antagonists. Some also inhibit thromboxane synthetase.